Endometrial (Uterine) Cancer Clinical Trials

Researchers want to see how well the drugs sapanisertib and serabelisib (PIKTOR) work when given together to treat endometrial cancer. The people in this study have endometrial cancer that has come back or grown after treatment. They also have genetic changes in the pathway that PIKTOR targets. These changes can cause resistance to chemotherapy drugs.

In this study, researchers are comparing selumetinib plus olaparib to selumetinib alone to treat endometrial or ovarian cancer. People in this study have cancer that came back or keeps growing after treatment. In addition, their cancers have a change (mutation or variant) in a RAS gene.

Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.

If you take part in this study, you will be randomly assigned to receive one of these therapies:

The purpose of this study is to assess the safety and effectiveness of the investigational drug MORAb-202 in people with endometrial or ovarian cancer. MORAb-202 targets a protein called FRA on cancer cells and delivers eribulin (a chemotherapy drug) directly to these cells, which may slow or stop cancer growth. MORAb-202 is given intravenously (by vein).

Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.

The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.

This purpose of this study is to assess whether adding trastuzumab/hyaluronidase-oysk or pertuzumab/trastuzumab/hyaluronidase-zzxf to the usual chemotherapy (paclitaxel and carboplatin) shrinks tumors in patients with HER2-positive endometrial serous carcinoma or carcinosarcoma.

However, most cancer recurrences happen within the first year of treatment. Long-term ICI therapy can also cause lasting side effects and be expensive. Doctors are therefore interested in finding ways to identify which patients can stop maintenance therapy sooner.

After endometrial cancer surgery, there is a risk that the cancer will come back. Combining a shorter course of radiation treatment with chemotherapy may decrease the chance of endometrial cancer recurring.